The Central Drugs Standard Control Organization (CDSCO) has announced that all applications related to Post Approval Changes (PAC) for recombinant DNA (r-DNA) products must now ...

The Monoclonal Antibodies Market has emerged as one of the most transformative sectors within the global biopharmaceutical ...

Genome editing-based therapies typically aim to treat disease by correcting underlying genetic mutations in patient's cells.

Drug delivery researchers have vastly improved the potential of genetic therapies by overcoming the challenge of consistently getting genes and gene-editing tools where they need to be within cells.

Cancers emerge from many different paths. One path begins early, in embryonic development, when a protein complex called PRC2, which regulates cell differentiation, identity, and plasticity, becomes ...